DOD FY04 Prostate Cancer Research Program (PCRP) Exploration - Hypothesis Development Award (EHD)

The summary for the DOD FY04 Prostate Cancer Research Program (PCRP) Exploration - Hypothesis Development Award (EHD) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DOD FY04 Prostate Cancer Research Program (PCRP) Exploration - Hypothesis Development Award (EHD): The intent of the Exploration - Hypothesis Development Award is to provide funds to support initial exploration of innovative, untested, potentially groundbreaking concepts in prostate cancer. Results of studies conducted through an Exploration - Hypothesis Development Award may provide the scientific rationale upon which a new hypothesis can be based or may provide, for example, initial proof of principles of an innovative hypothesis. The award is designed to provide investigators with the opportunity to pursue serendipitous observations. Some gaps in supporting rationale may exist due to lack of available information. The Exploration - Hypothesis Development Award is not intended to support ongoing work. Therefore, the existence of preliminary data suggests that the research would be more appropriately submitted to a different award mechanism. Successfully completed Exploration - Hypothesis Development Awards are expected to lead to high-risk, potentially high-gain future research endeavors for this and other funding agencies. Due to the preliminary nature of the studies being supported by this award, projects involving human subjects or specimens will not be supported unless they are exempt under 32 CFR 219.101(b)(4) or eligible for expedited review (45 CFR 46.110; 21 CFR 56.110). Studies that do not qualify for exempt or expedited status during review at any level will be administratively withdrawn and will not be funded.